Pfizer has requested the U.S. Meals and Drug Administration (FDA) to develop the emergency use authorization of its COVID-19 vaccine to incorporate youngsters ages 12 to fifteen.
In an announcement on Friday (April 9), the corporate mentioned its request for expanded authorization relies on knowledge from its Part 3 trial in adolescents, which discovered the vaccine was 100% efficient on this age group.
“Pending regulatory choice, our hope is to make this vaccine obtainable to the 12-15-year-old age group earlier than the beginning of the 2021 faculty 12 months,” the corporate mentioned in a post on Twitter.
The vaccine is at present licensed for emergency use in individuals ages 16 and older, and Pfizer’s request requested the FDA to amend this authorization to permit the vaccine in adolescents. The corporate mentioned it plans to make comparable requests to regulatory authorities worldwide within the coming days.
Initially revealed on Dwell Science.